Medtronic (NYSE: MDT) reported Q4 EPS of $1.62, $0.04 better than the analyst estimate of $1.58. Revenue for the quarter came in at $8.93 billion versus the consensus estimate of $8.82 billion.

GUIDANCE:

Medtronic sees FY2026 EPS of $5.50-$5.60, versus the consensus of $5.83. The company is guiding to FY26 organic revenue growth of approximately 5%.

For earnings history and earnings-related data on Medtronic (MDT) click here.